{"url_path":"/sec/fhtx/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1822462/0001628280-26-045154-index.html","accession_number":"0001628280-26-045154","cik":"0001822462","ticker":"FHTX","issuer_name":"Foghorn Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1822462/0001628280-26-045154-index.html","primary_entity_key":"0001822462","primary_entity_name":"Foghorn Therapeutics Inc."},"word_count":443,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 24, 2026, Foghorn Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were submitted to the Company’s stockholders at the Annual Meeting:\n\n(i)     To elect Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall as Class III directors, each for a three-year term;\n\n(ii)    To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026;\n\n(iii)    To approve, on an advisory basis, the compensation of the Company's named executive officers; and\n\n(iv)    To approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers.\n\nThe proposals are described in detail in the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on April 30, 2026.\n\nThe number of shares of common stock entitled to vote at the Annual Meeting was 58,713,922. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 51,708,896. The final votes regarding each proposal are set forth below:\n\n(i)    Election of directors.\n\nThe stockholders of the Company elected each of the following director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.\n\nDirector Nominee\n\nVotes For\nVotes AgainstAbstentionsBroker Non-Votes\n\nDouglas Cole, M.D.35,118,79810,987,0925,5625,597,444\n\nSimba Gill, Ph.D.45,956,872151,1453,4355,597,444\n\nB. Lynne Parshall44,412,2581,695,5303,6645,597,444\n\n(ii)    Ratification of appointment of independent registered public accounting firm.\n\nThe stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026.\n\nVotes For\n\nVotes Against\n\nAbstentions\nBroker Non-Votes\n\n51,661,23847,4312270\n\n(iii)    Approval, on an advisory basis, of Foghorn's named executive officers.\n\nThe stockholders of the Company approved, on an advisory basis, the compensation paid to the Company's named executive officers.\n\nVotes For\n\nVotes Against\n\nAbstentions\nBroker Non-Votes\n\n45,637,005468,9475,5005,597,444\n\n(iv)    Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of Foghorn's named executive officers.\n\nThe stockholders of the Company approved, on an advisory basis, the frequency of one year for future advisory votes on executive compensation.\n\nOne Year\n\nTwo Years\nThree YearsAbstentionsBroker Non-Votes\n\n45,574,4073,577520,62112,8475,597,444\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nFOGHORN THERAPEUTICS INC.\n\n \n\nBy:/s/ Ryan Maynard\n\nRyan Maynard\n\nChief Financial Officer\n\nDate: June 24, 2026"}